Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Conditions

Lambert-Eaton Myasthenic Syndrome 4Rare Diseases 1Neurologic Manifestations 1Myasthenia Gravis 1Mental Disorders 1

Interventions

Bevacizumab 3Radiosurgery 2Irinotecan 2pembrolizumab 1Vorinostat 1Valproic Acid 1Thalidomide 1Temozolomide 1Surveys and Questionnaires 1Sorafenib 1Sildenafil Citrate 1Pliability 1Nivolumab 1Morphine 1Methadone 1Exercise 1Equipment and Supplies 1Eating 1Carboplatin 1Amifampridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neurologic Manifestations × Amifampridine × Clear all
NCT00004832 2015-03-25

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

FDA Office of Orphan Products Development

Phase NA Completed
26 enrolled

Mental Disorders, Neurologic Manifestations, Lambert-Eaton Myasthenic Syndrome, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡